Clarus Therapeutics Holdings Inc. [CRXT] is -78.04% lower this YTD. Is it still time to buy?

Related

Clarus Therapeutics Holdings Inc. [NASDAQ: CRXT] closed the trading session at $0.53 on 05/10/22. The day’s price range saw the stock hit a low of $0.5005, while the highest price level was $0.5985. The company report on May 10, 2022 that Clarus Therapeutics Announces Notice of Allowance for Patent Claims Covering CLAR-121 (Testosterone + Anastrozole) for Treatment of Androgen-Mediated Autoimmune Inflammatory Mastitis.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored

Initial focus for CLAR-121 is the treatment of periductal mastitis (PDM) in women.

Clarus is seeking Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in the second quarter of 2022.

The stocks have a year to date performance of -78.04 percent and weekly performance of -24.39 percent. The stock has been moved at -89.83 percent over the last six months. The stock has performed -56.25 percent around the most recent 30 days and changed -57.64 percent over the most recent 3-months.

If compared to the average trading volume of 12.48M shares, CRXT reached to a volume of 7590461 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Here’s what leading stock market gurus have to say about Clarus Therapeutics Holdings Inc. [CRXT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRXT shares is $5.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRXT stock is a recommendation set at 1.80. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for Clarus Therapeutics Holdings Inc. is set at 0.28, with the Price to Sales ratio for CRXT stock in the period of the last 12 months amounting to 1.05.

CRXT stock trade performance evaluation

Clarus Therapeutics Holdings Inc. [CRXT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -24.39. With this latest performance, CRXT shares dropped by -56.25% in over the last four-week period, additionally sinking by -89.83% over the last 6 months – not to mention a drop of -94.69% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRXT stock in for the last two-week period is set at 39.20, with the RSI for the last a single of trading hit 35.46, and the three-weeks RSI is set at 41.10 for Clarus Therapeutics Holdings Inc. [CRXT]. The present Moving Average for the last 50 days of trading for this stock 1.0501, while it was recorded at 0.6205 for the last single week of trading, and 3.9664 for the last 200 days.

Clarus Therapeutics Holdings Inc. [CRXT]: An insightful look at the core fundamentals

Clarus Therapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.80.

Clarus Therapeutics Holdings Inc. [CRXT]: Insider Ownership positions

There are presently around $2 million, or 78.40% of CRXT stock, in the hands of institutional investors. The top three institutional holders of CRXT stocks are: BRACEBRIDGE CAPITAL, LLC with ownership of 2,002,495, which is approximately 0% of the company’s market cap and around 6.10% of the total institutional ownership; ARMISTICE CAPITAL, LLC, holding 1,929,876 shares of the stock with an approximate value of $1.05 million in CRXT stocks shares; and VANGUARD GROUP INC, currently with $91000.0 in CRXT stock with ownership of nearly New of the company’s market capitalization.

8 institutional holders increased their position in Clarus Therapeutics Holdings Inc. [NASDAQ:CRXT] by around 2,155,025 shares. Additionally, 9 investors decreased positions by around 197,815 shares, while 2 investors held positions by with 1,886,257 shares. The mentioned changes placed institutional holdings at 4,239,097 shares, according to the latest SEC report filing. CRXT stock had 7 new institutional investments in for a total of 2,148,048 shares, while 8 institutional investors sold positions of 167,393 shares during the same period.